Asenapine pharmacokinetics and tolerability in a pediatric population

Pharmacokinetics in pediatric population

Population pharmacokinetics of omeprazole in a random Iranian population

Background: Omeprazole is metabolized predominantly by CYP2C19, a polymorphically expressed enzymes that show marked interindividual and interethnic variation. These variations cause a substantial differences that have been reported in the pharmacokinetics of omeprazole. The aim of the present study was to evaluate the pharmacokinetic parameters of omeprazole in a random Iranian population. Met...

Tolerability and Pharmacokinetics

Background and Purpose—UK-279,276, a recombinant glycoprotein, binds selectively to the CD11b/CD18 integrin on neutrophils and has the potential to modulate the neuroinflammation associated with acute stroke. After preclinical evidence of neuroprotection, UK-279,276 has entered clinical development. The purposes of this study were to evaluate the safety and tolerability of UK-279,276 and to exa...

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.

Micafungin (FK463) is a new parenteral echinocandin. A multicenter, phase I, open-label, sequential-group dose escalation study was conducted to assess the safety, tolerability, and pharmacokinetics of micafungin in neutropenic pediatric patients. A total of 77 patients stratified by age (2 to 12 and 13 to 17 years) received micafungin. Therapy was initiated at 0.5 mg/kg per day and escalated t...

population pharmacokinetics of omeprazole in a random iranian population

background: omeprazole is metabolized predominantly by cyp2c19, a polymorphically expressed enzymes that show marked interindividual and interethnic variation. these variations cause a substantial differences that have been reported in the pharmacokinetics of omeprazole. the aim of the present study was to evaluate the pharmacokinetic parameters of omeprazole in a random iranian population. met...